Objective :To investigate the anti -tumor mechanism and therapeutic effect of 131I -histamine -indomethacin in mice baring Lewis lung cancer. Methods; 131I - histamine - indomethacin was administrated by garaged for the mice. At each time point,the sliced underwent HE staining for observing the necrosis of tumors, to observe the 131I - His - IN in the cellular using autoradiography (ARG). The 18F - FDG PET - CT groups received 18F - FDG PET - CT scan, then the mice were administrated by gavage for saline, 131I, IN, His - IN,131I - His - IN respectively, Tid/7days. 7 days later, all the five groups received 18F - FDG PET - CT scan again, calculating the SUVmax later. Results: With ARG,131I - His - IN concentrated selectively in tumor tissues. The black silver particle concentrated distribution in the nucleus,cytoplasm. 8h after giving "'I - His - IN, the radioactivity uptake in tumor tissue was higher than other organs(F=3.46,P<0.05). For 18F-FDG PET-CT groups, the tumor tissue SUVmax was lower than the control, especially for 131I - His - IN group. Tumor inhibitory rate in 131I - His - IN group was higher than other groups(54. 8% ). Over time, the VEGF level decreased gradually, the drug groups were lower than the control ones, too. The necrotic tissue increased with the time lapse in the pathology of the tumor. Conclusion; 131I -histamine - indomethacin can inhibit Lewis lung cancer. It aimed at the nucleus, cytoplasm. It could reduce the VEGF and decrease tumor inhibitory rate.131I - His - IN could improve the anti - tumor function. "F- FDG PET -CT could be used for curative effect and prognosis monitoring.%目的:通过放射自显影技术(ARG)、血管内皮生长因子(VEGF)含量测定及18F-FDG PET-CT显像等方式观察131碘-组胺-吲哚美辛(131I-His-IN)对小鼠荷Lewis肺癌的治疗效果及作用机制.方法:小鼠灌胃给予131I-His-IN后,于不同时间点测定肿瘤组织及其它非肿瘤器官放射性计数,制成ARG切片及HE病理切片.给予不同药物治疗前、后均行18F-FDG PET-CT显像,获半定量最大标准摄取值(SUVmax)及抑瘤率.应用ELISA免疫分析法分析血清标本VEGF含量.结果:ARG显示:131I-His-IN选择性浓聚于肿瘤组织,黑色银颗粒主要在肿瘤细胞浆及细胞核分布.给药后8h肿瘤组织与肝脏、肾脏、肌肉、血液的放射性摄取比差异显著(F=3.46,P＜0.05),肿瘤组织放射性强度达到最大值(52％).病理显示肿瘤坏死组织随时间推移逐渐增多;18F-FDG PET-CT显像,治疗后的肿瘤组织SUVmax值降低,差异具有统计学意义(F=6.54,P＜0.05),抑瘤率以131I-His-IN降低最为显著达54.8％;血清中VEGF含量随时间推移逐渐下降,以131I-His-IN及His-IN组下降明显,差异具有统计学意义(F=7.74,P＜0.05).结论:放射自显影观察到131I-His-IN选择性浓聚于肿瘤组织上,作用靶点以胞核、胞浆为主,胞膜也有部分存在;随时间推移瘤组织坏死逐渐增加、抑瘤率升高、血清中VEGF水平逐渐下降,证明131I-His-IN具有明显的抗肿瘤作用.18F-FDGPET-CT显像通过SUVmax值动态变化,可用于监测抗肿瘤药物的疗效.
展开▼
